Search results
Added:
5 months ago
Source:
Radcliffe CVRM
A new real-world evidence study suggests that the incretin-based medicines tirzepatide and semaglutide have comparable cardiovascular (CV) benefits for patients with type 2 diabetes (T2D) and elevated CV risk.¹ While clinical trials have shown benefits for both drugs, the lack of direct head-to-head comparisons has left uncertainty regarding the optimal treatment choice in clinical practice.To…
View more
Added:
6 months ago
Source:
Radcliffe CVRM
The SURPASS-PEDS trial has found that tirzepatide significantly improved glycaemic control and reduced body mass index (BMI) in children and adolescents with type 2 diabetes (T2D) compared with placebo.¹ Youth-onset T2D presents unique challenges, as current treatments often show lower efficacy than in adults, and the disease course can be more aggressive.²Tirzepatide is a dual glucose-dependent…
View more
Added:
11 months ago
Source:
Radcliffe CVRM
AUTHOR: Greg GuilloryInterim findings from the Phase 3 ESSENCE trial (NCT04822181) published in the New England Journal of Medicine show that weekly treatment with semaglutide 2.4 mg significantly resolves metabolic dysfunction–associated steatohepatitis (MASH) and reduces liver fibrosis. At 72 weeks, semaglutide induced histological resolution of steatohepatitis in 62.9% of patients compared…
View more
Added:
5 months ago
Source:
Radcliffe CVRM
New findings from the IMPACT trial suggest that the GLP-1–glucagon dual receptor agonist, pemvidutide, shows promise in treating metabolic dysfunction-associated steatohepatitis (MASH), a condition with a high global prevalence and limited therapeutic options.¹˒²Pemvidutide is a dual receptor agonist that targets both the glucagon-like peptide-1 (GLP-1) and glucagon receptors, which are involved…
View more
Added:
7 months ago
Source:
Radcliffe CVRM
Completing the National Health Service Diabetes Prevention Programme (NHS DPP) is associated with a lower incidence of not only type 2 diabetes (T2D) but also multiple other long-term conditions (LTCs), according to a new retrospective observational study published in Nature Medicine.¹This study analysed data from adults in England with non-diabetic hyperglycaemia (NDH) who were referred to the…
View more
Added:
1 year ago
Source:
ACC 2025
Watch our comprehensive coverage of ACC 2025's top trials here.The American College of Cardiology has announced the late-breaking trial and featured clinical research presentations for its 74th annual scientific sessions.ACC 2025 will be held from the 29th to 31st March at McCormick Place in Chicago.View the full programme here.Late-Breaking Clinical Trials I (Session 102)Saturday 29th March, 09…
View more